Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
暂无分享,去创建一个
Sun-Hee Kim | C. Jung | J. Jang | Yujin Han | Hyun-Young Kim | HeeKyung Kim
[1] F. Fabris,et al. Clinical effect of CALR allele burden in patients with essential thrombocythemia , 2021, Annals of Hematology.
[2] N. Nagy,et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. , 2018, Leukemia research.
[3] E. Padron,et al. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. , 2016, Hematology/oncology and stem cell therapy.
[4] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[5] F. Al-Shahrour,et al. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.
[6] C. Pecquet,et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.
[7] M. Cazzola,et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms , 2015, Leukemia.
[8] R. Gale,et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. , 2015, Leukemia research.
[9] A. Tefferi,et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. , 2014, Blood.
[10] E. Solary,et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution , 2014, Leukemia.
[11] A. Tordai,et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations , 2014, Haematologica.
[12] M. Cazzola,et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.
[13] P. Guglielmelli,et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.
[14] A. Tefferi,et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact , 2014, Leukemia.
[15] F. Passamonti,et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.
[16] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[17] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[18] P. Guglielmelli,et al. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment , 2011, Therapeutic advances in hematology.
[19] H. Kreipe,et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. , 2009, Experimental hematology.
[20] M. Michalak,et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. , 2009, The Biochemical journal.
[21] M. Møller,et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype , 2007, European journal of haematology.
[22] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.